MARKET

FENC

FENC

Fennec Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.76
-0.20
-2.51%
After Hours: 7.76 0 0.00% 16:00 11/23 EST
OPEN
7.90
PREV CLOSE
7.96
HIGH
7.93
LOW
7.65
VOLUME
88.92K
TURNOVER
--
52 WEEK HIGH
10.67
52 WEEK LOW
4.650
MARKET CAP
200.28M
P/E (TTM)
-9.4278
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
New Strong Sell Stocks for November 19th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
Zacks · 4d ago
Fennec Pharmaceuticals Q3 EPS $(0.24) Down From $(0.09) YoY
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.24) per share. This is a 166.67 percent decrease over losses of $(0.09) per share from the same period last year.
Benzinga · 11/16 12:18
Fennec Pharmaceuticals EPS misses by $0.05
Fennec Pharmaceuticals (FENC): Q3 GAAP EPS of -$0.24 misses by $0.05.Cash and cash equivalents were $33.2 million as of September 30, 2020.Press Release
Seekingalpha · 11/16 12:15
Here's Why We're Not Too Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 11/05 12:46
Fennec Announces Issuance Of US Patent For PEDMARK
RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation
Benzinga · 09/21 10:06
Fennec Announces Issuance of U.S. Patent for PEDMARK™
RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric
GlobeNewswire · 09/21 10:00
EQUITY ALERT: ROSEN, A LEADING AND RANKED FIRM, Announces Investigation of Securities Claims Against Fennec Pharmaceuticals Inc. FENC
Business Wire · 08/17 15:54
Mid-Afternoon Market Update: Dow Rises 1%; Kforce Shares Climb On Upbeat Q2 Results
Toward the end of trading Tuesday, the Dow traded up 1.06% to 28085.22 while the NASDAQ fell 0.22% to 10,944.77. The S&P also rose, gaining 0.45% to 3,375.46.
Benzinga · 08/11 18:40
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FENC. Analyze the recent business situations of Fennec Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FENC stock price target is 15.00 with a high estimate of 21.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 78
Institutional Holdings: 16.25M
% Owned: 62.97%
Shares Outstanding: 25.81M
TypeInstitutionsShares
Increased
14
403.36K
New
20
20.53K
Decreased
19
465.05K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Independent Director
Khalid Islam
Chief Executive Officer/Director
Rostislav Raykov
Chief Financial Officer
Robert Andrade
Other
Shubh Goel
Independent Director
Marco Brughera
Independent Director
Jodi Cook
Independent Director
Adrian Haigh
Independent Director
Chris Rallis
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FENC
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Fennec Pharmaceuticals Inc stock information, including NASDAQ:FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.